Psychedelic Therapy Contraindications: Who Should Pause First

Why This Conversation Has to Come First

Interest in psychedelic-assisted therapy has grown considerably in the past several years, and for reasons that are grounded in real clinical evidence. Psilocybin in particular has shown meaningful results for depression, anxiety, and alcohol use disorder in controlled research settings. But the trials that produced those results also screened participants rigorously, and who was excluded from those trials matters just as much as who was included.

A contraindication is not a judgment. It is a clinical signal that the risk-to-benefit calculation looks different for you than it does for the average participant in a research study. Some contraindications are absolute, meaning the risk is clear enough that no responsible guide or program should proceed. Others are relative, meaning the situation is more nuanced and a qualified professional may be able to help you think through a safer path. Knowing the difference is the starting point for any honest intake process.

Absolute Contraindications: Where the Risk Is Clear

Personal History of Psychosis or Schizophrenia

This is the most consistently cited absolute contraindication across clinical guidelines and research protocols. Classic psychedelics, including psilocybin and LSD, act primarily on serotonin 2A receptors. In people with a personal history of psychosis or schizophrenia, that same receptor activation can worsen existing symptoms or trigger a new episode. The UCSF Psychedelics Division notes that while prolonged psychosis is rare in the general population, the risk is substantially elevated for people with personal histories of schizophrenia, schizoaffective disorder, or psychotic depression.

Most modern clinical trials have excluded this population entirely, which means safety data for this group is limited. The clinical guidance that does exist points in one direction: if you have experienced psychotic symptoms at any point, whether formally diagnosed or not, the appropriate next step is a conversation with a psychiatrist who understands psychedelics, not a session.

Personal History of Bipolar I Disorder or Mania

This category requires some unpacking, because the picture is not the same across all bipolar diagnoses. Bipolar II, which involves hypomania rather than full mania, has been studied in small pilot trials with psilocybin, and early results have not shown increases in manic symptoms. Bipolar I, which includes full manic episodes, carries a different risk profile.

Research published in the Journal of Affective Disorders found that people with a personal or family history of bipolar disorder who used psychedelics showed increased manic symptoms over time. Most clinical experts now advise against psychedelic use in anyone with a history of full mania. The concern is not theoretical; it is grounded in enough case data that exclusion from research trials has become standard practice for this population. If your history involves Bipolar I, this is a firm pause point that requires direct medical input before anything else happens.

Current Lithium Use

The SSRI psychedelic interaction gets most of the attention in public discourse, but the lithium interaction is the one with clearer and more serious risk. An analysis of psychedelic experience reports, published in Pharmacopsychiatry, found that coadministration of classic psychedelics with lithium, unlike with other mood stabilizers such as lamotrigine, is consistently associated with a meaningful increase in seizure risk. The mechanism is not fully understood, but the signal is consistent enough across sources that most clinical frameworks treat it as an absolute contraindication.

Oregon’s licensed psilocybin program requires anyone who has taken lithium within the past 30 days to be ineligible for services. If you are taking lithium for mood stabilization, the path forward involves working with your prescribing physician first. That is not a bureaucratic hurdle; it is how this gets done safely.

Active Suicidal Ideation with Intent or a Current Plan

Psychedelics intensify emotional experience, sometimes substantially. For someone in acute crisis, that amplification carries real risk of destabilization. Past suicidal thoughts that have resolved are not a disqualifier in most clinical frameworks, but current active ideation with intent or a plan is a clear contraindication. Stabilization has to come first. This is not a situation where an altered-state experience is appropriate as an accelerant toward feeling better.

Relative Contraindications: Where the Conversation Is More Complex

SSRIs and SNRIs

The SSRI psychedelic interaction is one of the most frequent questions seekers bring to the JourneyOM team, and the honest answer involves acknowledging real uncertainty. Here is what the research shows so far.

SSRIs and SNRIs work in part by downregulating serotonin 2A receptors over time. Since psilocybin’s effects depend on activating those same receptors, long-term SSRI use appears to blunt the psychedelic experience, sometimes significantly. A retrospective survey and several small controlled trials have confirmed this attenuation effect. A 2024 study published in the Journal of Psychopharmacology examined outcomes in participants who discontinued SSRIs before psilocybin therapy and found that discontinuation itself may complicate treatment response, suggesting there is no clean solution in either direction.

Separately, a 2025 scoping review concluded that the risk of serotonin syndrome when combining classic psychedelics with SSRIs has been overstated in earlier literature, based on more recent pharmacological analysis. The concern has not disappeared, but it is no longer presented as a near-certain danger. The practical implication is that if you are currently on an SSRI or SNRI, the decision about whether, when, and how to adjust that medication belongs in a conversation with the physician who prescribed it. Tapering or discontinuing without medical supervision in anticipation of a psychedelic experience is not a shortcut; it is a separate risk.

Cardiac Conditions

Classic psychedelics produce temporary increases in heart rate and blood pressure during the experience. For most healthy adults, those changes are well tolerated. For people with pre-existing cardiovascular conditions, the picture requires more careful evaluation before anything else can be assessed.

A review published in Nature Cardiovascular Research noted that safety data on psychedelic use in people with established cardiovascular disease is limited. Cardiac complications including ventricular dysfunction have been reported in rare cases following psilocybin ingestion, primarily at high doses or in people with underlying medical vulnerabilities. The review from Massachusetts General Hospital is explicit that this population warrants careful clinical evaluation before proceeding.

Specific situations that require cardiology input include uncontrolled hypertension, significant arrhythmia, recent myocardial infarction, heart failure, and structural cardiac abnormalities. Having a cardiac history does not automatically close the door on psychedelic therapy, but it means the screening process needs input from your cardiologist, not just a wellness intake form. This matters because many people exploring this space are doing so for depression or anxiety that coexists with other health conditions, and the two conversations cannot be kept separate.

MAOIs and Ayahuasca-Specific Risks

Ayahuasca contains beta-carboline compounds that inhibit monoamine oxidase, which is what makes the DMT component orally active. That MAOI activity creates a distinct risk profile compared to other psychedelics. Combining ayahuasca with antidepressants, particularly SSRIs, tricyclics, or other serotonergic medications, carries a genuine risk of serotonin syndrome. This is a pharmacological interaction with documented serious consequences, not a theoretical concern. If you are considering ayahuasca and are on any psychiatric medication, the conversation with your prescribing physician is not optional.

Pregnancy and Breastfeeding

There is no safety data on psychedelic use during pregnancy or while breastfeeding. The absence of evidence is not evidence of safety, and this category is a clear pause point until research exists to say otherwise.

Significant Trauma Without Stabilization

This is less a medical contraindication and more a clinical one, but it belongs on this list because it is frequently underestimated. Psychedelics can open emotional material rapidly and with considerable force. People who have not yet developed foundational coping skills or a safety plan around significant trauma are at higher risk of a destabilizing experience. This follows the same logic as exposure-based trauma therapies, which are not typically the first step in trauma treatment either. Preparation matters, and having a professional guide through that preparation is part of what makes an experience productive rather than retraumatizing.

What Good Screening Actually Looks Like in Practice

A responsible intake process does not skip the hard questions. It asks about psychiatric history in detail, including family history of bipolar disorder and psychosis. It asks about current and recent medications, including supplements and herbal preparations that may carry relevant interactions. It asks about cardiac history, current mental health stability, and support structures for integration after the experience.

Thorough screening is not gatekeeping for its own sake. It is how responsible operators protect the people they work with, and it is one of the clearest signals that a program takes safety seriously. When a guide or service provider asks these questions carefully and honestly, that reflects the quality of the program, not an obstacle to getting started.

At JourneyŌM, the intake process is designed to surface these considerations early. If something in your history suggests that a standard supported experience is not the right fit, we will say so directly. We will also help you think through what alternatives might be more appropriate, whether that means working with your physician to address a relative contraindication or considering a different therapeutic modality altogether. Telling people what they want to hear is not part of how we work.

A Note on the Current Legal Landscape

Psilocybin remains a Schedule I controlled substance under federal law in the United States as of 2026. Legally supported access exists through state-licensed programs in Oregon and Colorado, as well as through approved clinical trials. Outside of those frameworks, people are often navigating unregulated retreat or underground settings where screening quality varies significantly.

This is where understanding psychedelic therapy contraindications matters most. In a clinical trial, a professional team handles screening. In an unregulated setting, that responsibility falls more heavily on you and whoever is supporting your experience. Understanding what to look for in your own history is not just useful information; it is a meaningful part of keeping yourself safe in a landscape that has not yet caught up to the level of public interest.